NGNE
Neurogene Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.60
+2.63%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.2x
Market Cap
$772.44M
MomentumView details →
1D Return
+2.63%
YTD Return
+86.21%
RSI (14)
54.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.2x
Market Cap
$772.44M
RSI (14)
54.8
MomentumView details →
1D Return
+2.63%
YTD Return
+86.21%
SummaryUpdated Jun 1, 2026
Neurogene Inc. (NASDAQ:NGNE) is a clinical-stage biotechnology company founded in 2014 and headquartered in New York, New York. The company specializes in developing gene therapies for rare neurological diseases, focusing on conditions that primarily affect children and have limited or no treatment options. Since its initial public offering in 2014, Neurogene has been advancing its pipeline of investigational treatments through clinical trials, with its lead programs targeting Rett syndrome and Batten disease.
Similar companies
Latest newsMore news →
Neurogene Inc. granted non-qualified stock options to purchase 38,330 shares of common stock to two new employees as inducement grants on September 1, 2026.1h agoNeurogene Inc. completed an oversubscribed financing raising approximately $144 million in gross proceeds, with net proceeds of approximately $134.8 million from a July 2026 public offering.25d ago